ASSEMBLY BIOSCIENCES INC

ound

On May 30, 2018, we adopted the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan, and on May 20, 2021, we adopted the Assembly Biosciences, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (the ESPP). As of April 1, 2024, there were 53,687 shares reserved for issuance under the ESPP. On March 13, 2024, the Board, upon the recommendation of the Compensation Committee and subject to the approval of our stockholders at the Annual Meeting, approved the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Purchase Plan (the Amended ESPP) to increase the number of shares reserved under the ESPP from 108,333, as adjusted due to our 1-for-12 reverse stock split that was effective in February 2024, to 164,500 and to eliminate the cap on the number of shares of common stock that may be issued to any employee under the ESPP per offering period and either relying on the statutory limit in Section 423 of the Code or such lesser number of shares as determined by the Administrator of the Amended ESPP from time to time. Based solely on the closing price of our common stock reported on The Nasdaq Global Select Market on April 1, 2024, the maximum aggregate market value of the 109,854 shares of common stock that could potentially be issued under the Amended ESPP is approximately $1,417,117.